Perrigo Completes Divestment of HRA Pharma Rare Diseases Business

Rhea-AI Summary

Perrigo Company plc (NYSE PRGO), a leader in Consumer Self-Care Products, has finalized the sale of its HRA Pharma Rare Diseases business to Esteve Healthcare for a total of up to €275 million. The deal includes an upfront cash payment of €190 million with adjustments, and potential earnout payments of up to €85 million based on sales milestones. Proceeds are expected to be used for debt repayment. In 2023, the divested business generated €50 million in net sales and €20 million in adjusted EBITDA. This transaction was anticipated in Perrigo's 2024 financial outlook.

Positive

• Perrigo secured up to €275 million from the divestment.
• Received €190 million upfront cash payment.
• Potential to earn up to €85 million in milestone payments.
• Proceeds to be used for debt repayment.

Negative

• Divested business generated €50 million in net sales and €20 million in adjusted EBITDA in 2023.

Insights

Financial Analyst

Perrigo's divestment of the HRA Pharma Rare Diseases business to Esteve Healthcare for up to €275 million is noteworthy for a few reasons. Firstly, the upfront cash payment of €190 million adds immediate liquidity, a point of interest for investors concerned with Perrigo's debt levels. Reducing debt is generally viewed favorably by the market as it can lower interest expenses and improve financial ratios.

From a financial health perspective, this move is aligned with Perrigo's strategic focus on its core Consumer Self-Care Products segment. Reinforcing this focus can potentially lead to a more streamlined business model and improved operational efficiency. The divestment allows Perrigo to redeploy resources towards operations that have better growth prospects and higher margins.

However, it's important to note that the HRA Pharma Rare Diseases business achieved net sales of approximately €50 million and adjusted EBITDA of €20 million in 2023. Investors should consider the trade-off between the immediate cash influx and the loss of a revenue stream. The potential earnout payments of up to €85 million are contingent on sales milestones, which introduces some uncertainty.

Overall, this transaction is likely positive for Perrigo in the short-term due to debt reduction, but the long-term impact will depend on how effectively the company reinvests the proceeds.

Market Research Analyst

Divesting a rare diseases segment reflects Perrigo's decision to concentrate on its core strengths in Consumer Self-Care Products. This can be a strategic move to capture a larger share in a growing market. The Consumer Self-Care Products industry has been expanding, driven by increasing consumer awareness and preference for over-the-counter health solutions. By reallocating focus and resources, Perrigo may position itself better to capitalize on these trends.

However, the sale to Esteve Healthcare also indicates that the rare diseases segment, while profitable, might not align with Perrigo's long-term growth strategy. This could suggest that Perrigo sees more significant growth opportunities in other areas. Investors should watch for how Perrigo's market positioning evolves and whether the company makes any notable acquisitions or product innovations in the Consumer Self-Care space.

While this divestment could streamline operations, it’s important to monitor whether the projected debt repayment leads to tangible financial improvements. The move might make Perrigo more appealing to a specific investor demographic interested in consumer health trends.

DUBLIN, July 10, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that it has completed the previously announced divestment of the HRA Pharma Rare Diseases business to Esteve Healthcare, S.L. ("ESTEVE") for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million, subject to customary net debt and working capital adjustments, and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones. Perrigo expects to redeploy proceeds from the divestment for debt repayment.

The impact from this transaction was included in the Company's previously issued 2024 outlook. In 2023, the HRA Pharma Rare Diseases business delivered net sales of approximately €50 million and adjusted EBITDA of approximately €20 million.

About Perrigo

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com. 

Perrigo Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "forecast," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: supply chain impacts on the Company's business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; the impact of the wars in Ukraine and the Middle East and any escalation thereof, including the effects of economic and political sanctions imposed by other countries related thereto; the outbreak or escalation of conflict in other regions where we do business; future impairment charges, if we determine that the carrying amount of specific assets may not be recoverable from the expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding the Company's ability to obtain and maintain its regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of the coronavirus (COVID-19) pandemic and its variants, or other epidemic or pandemic disease; the timing, amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; the Company's ability to achieve the benefits expected from its sale of its HRA Pharma Rare Diseases Business, including the potential earnout payments, and the risk that potential costs or liabilities incurred or retained in connection with that transaction may exceed the Company's estimates or adversely affect the Company's business or operations; the risk that potential costs or liabilities incurred or retained in connection with the sale of the Company's Rx business may exceed the Company's estimates or adversely affect the Company's business or operations; the Company's ability to achieve the benefits expected from the acquisitions of Héra SAS ("HRA Pharma") and Nestlé's Gateway infant formula plant along with the U.S. and Canadian rights to the GoodStart® infant formula brand and other related formula brands ("Gateway") and/or the risks that the Company's synergy estimates are inaccurate or that the Company faces higher than anticipated integration or other costs in connection with the acquisitions; risks associated with the integration of HRA Pharma and Gateway, including the risk that growth rates are adversely affected by any delay in the integration of sales and distribution networks; the consummation and success of other announced and unannounced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including the Company's ability to achieve the expected benefits from its  ongoing restructuring programs described herein.  Adverse results with respect to pending litigation could have a material adverse impact on the Company's operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2023, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURES
(in thousands)
(unaudited)
				Twelve Months Ended
	HRA Rare Diseases			December 31, 2023
	Loss from continuing operations(1)			$                                                                      (84,097)
	Income tax expense(2)			5,410
	Interest expense, net			—
	Depreciation and amortization			9,655
	EBITDA			(69,032)
	Impairment charges			89,978
	Adjusted EBITDA			20,946

	(1) The Rare Diseases reporting unit was a fully integrated component of the CSCI segment, and as a result reported values were not separately tracked. Loss from continuing operations is estimated for this purpose as revenue less cost of goods sold (determined in each case in accordance with U.S. GAAP), less a proportionate share of selling, general and administrative expenses of the CSCI reporting segment, based on the fraction of revenue of the Rare Diseases business bore to CSCI revenue. Depreciation and amortization is based on U.S. GAAP charges for the Rare Diseases business.
	(2) Calculation of the effective tax rate for the Rare Disease business is impractical. Accordingly, Income tax expense is estimated for this purpose based on the French corporate income tax rate in effect during the period, which we believe is a reasonable approximation of the effective tax rate that would be applicable to the business on a stand-alone basis.

View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-completes-divestment-of-hra-pharma-rare-diseases-business-302193470.html

SOURCE Perrigo Company plc

FAQ

What recent business transaction did Perrigo (PRGO) complete?

Perrigo completed the divestment of its HRA Pharma Rare Diseases business to Esteve Healthcare.

How much did Perrigo (PRGO) receive from the divestment of HRA Pharma Rare Diseases?

Perrigo received up to €275 million, including a €190 million upfront cash payment and up to €85 million in potential earnout payments.

What will Perrigo (PRGO) do with the proceeds from the HRA Pharma Rare Diseases divestment?

Perrigo plans to use the proceeds for debt repayment.

How much revenue did the HRA Pharma Rare Diseases business generate in 2023?

In 2023, the HRA Pharma Rare Diseases business generated approximately €50 million in net sales.

What was the adjusted EBITDA for the HRA Pharma Rare Diseases business in 2023?

The adjusted EBITDA for the HRA Pharma Rare Diseases business in 2023 was approximately €20 million.